Howard Grossberg
- Oncology top 10%
- Molecular Biology
- Genetics top 10%
- Radiology, Nuclear Medicine and Imaging top 10%
- Cancer Research
- Co-authors
- Y A TeramotoL. DemersKim LeitzelA. LiptonV. M. ChinchilliH HarveyKerstin KonradLaurence M. Demers
- Topics
- Cancer therapeutics and mechanisms (4 papers)HER2/EGFR in Cancer Research (3 papers)Estrogen and related hormone effects (2 papers)
- Cited by
- OncologyToxicologyCancer Research
- Partner nations
- United StatesSwitzerlandIndia
In The Last Decade
Howard Grossberg
12 papers receiving 716 citations
Peers
Comparison fields: 5 of 65
- Oncology 432
- Molecular Biology 270
- Genetics 201
- Radiology, Nuclear Medicine and Imaging 180
- Cancer Research 125
Countries citing papers authored by Howard Grossberg
This map shows the geographic impact of Howard Grossberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Howard Grossberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Howard Grossberg more than expected).
Fields of papers citing papers by Howard Grossberg
This network shows the impact of papers produced by Howard Grossberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Howard Grossberg. The network helps show where Howard Grossberg may publish in the future.
Co-authorship network of co-authors of Howard Grossberg
This figure shows the co-authorship network connecting the top 25 collaborators of Howard Grossberg. A scholar is included among the top collaborators of Howard Grossberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Howard Grossberg. Howard Grossberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 92 | |
| 2 | 44 | |
| 3 | 1 | |
| 4 | 247 | |
| 5 | 93 | |
| 6 | 70 | |
| 7 | 1 | |
| 8 | 32 | |
| 9 | 4 | |
| 10 | Phase I study of the combination of alpha-2 interferon and cisplatinum. | 13 |
| 11 | Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. | 143 |
| 12 | Treatment of advanced refractory lymphoma with teniposide and lomustine. | 3 |
About Howard Grossberg
Howard Grossberg is a scholar working on Reproductive Medicine, Genetics and Oncology, having authored 12 papers that have together received 743 indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (4 papers), HER2/EGFR in Cancer Research (3 papers) and Estrogen and related hormone effects (2 papers). The work is most often cited by research in Oncology (432 citations), Toxicology (42 citations) and Cancer Research (125 citations). Howard Grossberg has collaborated with scholars based in United States, Switzerland and India. Frequent co-authors include Y A Teramoto, L. Demers, Kim Leitzel, A. Lipton, V. M. Chinchilli, H Harvey, Kerstin Konrad, Laurence M. Demers, Harold A. Harvey and Richard J. Santen. Their work appears in journals such as Journal of Clinical Oncology, Cancer and The American Journal of Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.